Avalo Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 11 and June 12, 2026. Avalo Therapeutics, Inc. (AVTX), a Delaware corporation, reported an unregistered exchange of equity securities and material amendments to executive employment agreements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The report focuses on corporate governance and capital structure adjustments.
Material Changes
- Equity Exchange: The Company exchanged 4,294.675 shares of Series C non-voting convertible preferred stock for an identical number of newly created Series C-1 non-voting convertible preferred stock shares with an accredited investor. This exchange removes a beneficial ownership restriction, allowing the investor to increase their ownership limit from 4.99% to 9.99% of common stock upon conversion.
- Capital Structure: A Certificate of Designation was filed to establish the Series C-1 Preferred Stock. These shares rank in parity with Series C and Common Stock regarding dividends and liquidation and include broad-based weighted average anti-dilution protection.
- Executive Compensation: Employment agreements for the CEO, CFO, CMO, and Chief Business Officer were amended to modify severance and change-in-control provisions.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding business strategy or risks. The primary purpose is to disclose the specific terms of the equity exchange and executive contract amendments.
Executive Compensation Amendments
Effective June 12, 2026, amendments were made to the employment agreements of Garry A. Neil (CEO), Christopher Sullivan (CFO), Mittie Doyle (CMO), and Taylor Boyd (CBO). Key changes include:
- Termination without Cause/Good Reason: Executives are entitled to 12 months of base salary (18 months for the CEO), unpaid prior year bonuses, prorated current year bonuses, and COBRA coverage. Pre-amendment options vest in full upon termination.
- Change in Control (CIC) Termination: If termination occurs within a specific window around a CIC, executives receive 1.0x base salary (1.5x for CEO) plus 1.0x target bonus. All unvested time-based equity awards accelerate fully.
- CIC Vesting: In the event of a CIC, unvested equity awards will fully vest on the first anniversary of the CIC, provided the executive remains employed.
- 280G Limitation: Payments are subject to "golden parachute" reduction rules to avoid excise taxes if the after-tax amount is higher without the reduction.
Investor Verification Checklist
- Verify the total number of outstanding Series C Preferred Stock shares (4,085.379 remaining) and the conversion ratio of the new Series C-1 shares (1,000:1).
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific anti-dilution mechanics and dividend rights.
- Examine the amended employment agreements (Exhibits 10.1 through 10.4) to confirm specific salary figures and bonus targets not detailed in the summary.
- Confirm the identity of the accredited investor involved in the Series C to C-1 exchange.